Go6976

Print

Technical Data

Molecular Weight 377.42 Storage powder
Formula

C24H18N4O

-- -- --
CAS No. 136194-77-9 Synonyms N/A
Solubility (25°C) * In vitro DMSO 18 mg/mL warmed (47.69 mM)
Water Insoluble
Ethanol Insoluble
In vivo 0.5% CMC Na+1% Tween 80 30mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-12-propanenitrile

Biological Activity

Description Go6976 is a potent PKC inhibitor with IC50 of 7.9 nM, 2.3 nM, and 6.2 nM for PKC (Rat brain), PKCα, and PKCβ1, respectively. Also a potent inhibitor of JAK2 and Flt3.
Targets
JAK2 [2]
(Cell-free assay)
FLT3 [2]
(Cell-free assay)
PKCα [1]
(Cell-free assay)
PKCβ1 [1]
(Cell-free assay)
PKC [1]
(Rat brain)
2.3 nM 6.2 nM 7.9 nM
In vitro Go6976 have no effect on the kinase activity of the Ca(2+)-independent PKC subtypes delta, epsilon, and zeta. [1] Beside WT JAK2, Go6976 also inhibits the mutant forms (JAK2 V617F and TEL-JAK2) found in haematological malignancies, and has activity against mutant forms of FLT3. In AML cells, Go6976 reduces the survival to 55% of control in FLT3-ITD cases and to 69% in FLT3-WT samples.[2] Go 6976 potently inhibits HIV-1 induction by Bryostatin 1, tumor necrosis factor alpha, and interleukin 6. [3]
In vivo Go6976 (2.5 mg/kg i.p.), as a PKD inhibitor, effectively prevents LPS/D: -GalN-induced acute liver injury by inhibition of MAPKs activation to reduce TNF-α production, and significantly improves the survival of LPS/D-GalN-challenged mice. [4]
Features  

Protocol (Only for Reference)

Kinase Assay:

[1]

PKC Activity Assay In brief, for measuring PKCα, and PKCβ1 and PKC from rat brain, the assay mixture of 200 μl contains 50 mM HEPES (pH7.5), 5 mM MgCl2, 1 mM EDTA, 1.25 mM EGTA, 1.32 mM CaC12, 1 mM dithiothreitol, 1 μg of phosphatidylserine, 0.2 μg of diolein, 40 μg of histone Hi, 10 μM [γ-32P]ATP (1 μCi/ml), and 5-10 units (pmol of Pi/min) of PKC. Assays are started by the addition of [γ-32P]ATP, incubated for 5 min at 30 °C, stopped by the addition of 2 ml of 8.5% H3PO4, filtered through 0.45-μm nitrocellulose filters, and evaluated by scintillation counting.

Cell Assay:

[2]

Cell lines Primary AML cells
Concentrations 1 μM
Incubation Time 48 hours
Method

Cells are suspended at 2 × 105 per point in 200 μl RPMI/10% FCS. The inhibitor under investigation is added at the appropriate concentration and the cells incubated for 48 h at 37°C, 5% CO2. MTS activity is measured by CellTiter kit according to the manufacturers instructions. Results are expressed as a percentage of control (cells without inhibitor).

Animal Study:

[4]

Animal Models LPS/D-GalN-challenged mice
Formulation DMSO
Dosages 2.5 mg/kg
Administration i.p.
 

References

Customer Product Validation

, , Cell Signal, 2016, 28(9):1422-31.

Erk5 activation depends on Mek5, classical PKC and Mek1/2. MOVAS cells were serum-starved overnight and then treated for 1 h if not indicated otherwise with inhibitors targeting Jnk (SP600125, 10 μM), p38 (SB203580, 10 μM), Mek1/2 (CI-1040, 3 μM), Jak2 (AG490, 10 μM), Src (SU6656, 0.5 μM), Go6983 (PKC, 1 μM), Gö6976 (classical PKC, 1 μM), proteasomes (MG132, 25 μM), TPA (100 ng/ml for 15 min to activate PKCs or overnight to inhibit) and Mek5 (BIX02189, 1 μM), as well as Ca2 + chelators (EDTA, 2 mM; BAPTA-AM, 10 μM; both with 30 min preincubation), followed by stimulation with 20 ng/ml PDGF-BB for 10 min. Total cell lysates (TCL) were prepared and subjected to SDS-PAGE. Erk5 and PDGFRβ activities were measured by band shift and Tyr857 phosphorylation, respectively, using immunoblotting. Panel E and G show representative immunoblots.

Data from [Data independently produced by , , Infect Immun, 2017, e00087-17]

Inhibition of InlB-mediated entry by a chemical inhibitor of PKC-α. HeLa cells were treated with the indicated concentrations of the compound Go6976 699 or with the vehicle DMSO for 45 min before assessment of bacterial entry or cell viability. (i). The effect of Go6976 treatment on entry of Listeria expressing InlB is shown. Data are means +/- SEM from three experiments. *, P < 0.05 compared to the DMSO only (-) condition. (ii). Go6976 treatment did not affect viability of HeLa cells as measured with MTT assays. Results are mean +/- SEM values from three experiments. (iii). Go6976 treatment did not reduce entry of E. coli strain HB101 expressing the invasin protein of Yersinia enterocolitica (inv+ HB101). Data are mean +/- SEM values from three experiments.

Go6976 has been referenced in 2 publications.

PLEASE KEEP THE PRODUCT UNDER -20°C FOR LONG-TERM STORAGE.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most Selleck products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage.
We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

Chemical Structure

Return Policy

Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.

Toll Free:
(877) 796-6397
-- USA and Canada only --
Fax:
+1-713-796-9816
Orders:
+1-832-582-8158
sales@selleckchem.com
Tech Support:
+1-832-582-8158 Ext:3
tech@selleckchem.com
(Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.)
Website:
www.selleckchem.com